According to the CITIC Construction Investment Securities Research Report, the total number of batches issued in the vaccine industry in the first quarter of 2026 was 875, an increase of 14.1% over the previous year, mainly due to a sharp increase in the number of batches issued for products such as polio vaccine, measles vaccine, and hepatitis vaccine. In terms of research and development, in the first quarter of 2026, products or new indications such as Chengda Biotech Human Diploid Vaccine, Cansino MCV4 age extension and component 100 vaccine, and Kangtai Biotech quadrivalent influenza lysis vaccine were approved; many other products are in the marketing review stage. In 2026, the vaccine industry should pay attention to: 1) Innovative vaccine pipeline follow-up R&D nodes and external licensing expectations. 2) Improved product sales, combined with new product launches, contributing to increased performance. 3) Follow-up progress of equity changes.

According to the CITIC Construction Investment Securities Research Report, the total number of batches issued in the vaccine industry in the first quarter of 2026 was 875, an increase of 14.1% over the previous year, mainly due to a sharp increase in the number of batches issued for products such as polio vaccine, measles vaccine, and hepatitis vaccine. In terms of research and development, in the first quarter of 2026, products or new indications such as Chengda Biotech Human Diploid Vaccine, Cansino MCV4 age extension and component 100 vaccine, and Kangtai Biotech quadrivalent influenza lysis vaccine were approved; many other products are in the marketing review stage. In 2026, the vaccine industry should pay attention to: 1) Innovative vaccine pipeline follow-up R&D nodes and external licensing expectations. 2) Improved product sales, combined with new product launches, contributing to increased performance. 3) Follow-up progress of equity changes.